Boston Scientific to Acquire Valencia Technologies in Urology Push

Boston Scientific Corporation has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical device company focused on therapies for bladder dysfunction. The acquisition strengthens Boston Scientific’s position in the urology segment and expands its portfolio of treatments for overactive bladder and related conditions.

Valencia Technologies is best known for its eCoin System, an implantable tibial nerve stimulation (ITNS) device used to treat urge urinary incontinence (UUI), a condition linked to overactive bladder. The device received approval from the U.S. Food and Drug Administration in 2022 and is designed for patients who have not achieved sufficient relief from behavioral therapy or drug treatment, or who have responded well to percutaneous tibial nerve stimulation during testing.

Overactive bladder affects an estimated 30 million adults aged 40 and older in the United States, often leading to disrupted sleep, reduced work productivity, and diminished quality of life. Despite the scale of the condition, many patients do not progress to advanced therapies. The eCoin device, about the size of a coin, is implanted near the ankle and delivers scheduled electrical stimulation to the tibial nerve. This stimulation helps regulate bladder signaling pathways. Clinical trial data showed that around 68 percent of patients experienced a reduction of at least 50 percent in UUI episodes.

Boston Scientific said the addition of the eCoin System will complement its existing pelvic health and neuromodulation offerings, allowing physicians to select from a broader range of treatment options based on patient needs and disease severity.

Meghan Scanlon, Senior Vice President and President of Urology at Boston Scientific, said the acquisition aligns with the company’s strategy to expand access to minimally invasive therapies and support long-term patient management in urinary health.

Also Read: Alembic Pharma Wins USFDA Tentative Approval for Bosutinib

The transaction is expected to close in the first half of 2026, subject to regulatory approvals and standard closing conditions. Financial terms were not disclosed. Boston Scientific stated that the deal is expected to have an immaterial impact on adjusted earnings per share in 2026, with potential short-term GAAP dilution related to acquisition costs.